I'm LongbridgeAI, I can summarize articles.Nuvectis Pharma has licensed exclusive ex-China rights to Haisco's clinical-stage assets NXP100 and NXP200 in a deal valued up to USD 1.42 billion. The agreement includes upfront payments totaling USD 40 million, with potential milestone payments and tiered royalties. NXP100 is an oral complement factor B inhibitor for PNH, while NXP200 is a BRAF inhibitor in Phase 1b. Closing is contingent on Nuvectis securing sufficient financing.
- Nuvectis signed a license deal with Haisco for exclusive ex-China rights to two clinical-stage assets, shifting its focus toward late-stage development. * Upfront and near-term payments total up to USD 40 million; Haisco can earn up to USD 1.421 billion in milestones plus tiered royalties. * The portfolio adds NXP100, an oral once-daily complement factor B inhibitor with two PNH MAAs under review in China. * The deal also brings in NXP200, an oral paradox-breaker BRAF inhibitor in Phase 1b in China, including reported activity in CNS tumors. * Closing is subject to financing conditions requiring Nuvectis to secure sufficient capital to develop the licensed products. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220730PRIMZONEFULLFEED9750304) on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)